Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxime Frelaut

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
La Revue Du Praticien|February 11, 2022
[Immunotherapy for non-small-cell lung cancer]Maxime Frelaut, Benjamin Besse
La Revue Du Praticien|February 11, 2022
[Immunotherapy in oncology]Maxime Frelaut, Benjamin Besse
International Journal of Molecular Sciences|June 2, 2019
Hyperprogression under ImmunotherapyMaxime Frelaut, Christophe Le Tourneau, Edith Borcoman
Soins. Gerontologie|October 24, 2022
[The place of support care]Maxime Frelaut, Marion Aupomerol, Lena Degousée, et al.
Bulletin Du Cancer|April 10, 2021
[Why and how to assess older people with cancer?]Carole Helissey, Romain Geiss, Capucine Baldini, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 13, 2020
Pseudoprogression and Hyperprogression as New Forms of Response to ImmunotherapyMaxime Frelaut, Pauline du Rusquec, Alexandre de Moura, et al.
Cancer Treatment Reviews|April 26, 2022
The use of immunotherapy in older patients with advanced non-small cell lung cancerMarco Tagliamento, Maxime Frelaut, Capucine Baldini, et al.
Bulletin Du Cancer|April 26, 2021
[COVID-19 and patients with cancer: Experiment of a French comprehensive cancer center]Maxime Frelaut, Pauline Vaflard, Perrine Vuagnat, et al.
Cancers|December 11, 2019
Are Older Patients with Cervical Cancer Managed Differently to Younger Patients? An International SurveyMaxime Frelaut, Nienke De Glas, Ignacio Zapardiel, et al.
Age and Ageing|January 3, 2026
Reliability of the cumulative illness rating scale for geriatrics for assessing multimorbidity in older patients with cancer: results from the ELCAPA cohortMarc A Benderra, Philippe Caillet, Amélie Aregui, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
La Revue Du Praticien|February 11, 2022
[Immunotherapy for non-small-cell lung cancer]Maxime Frelaut, Benjamin Besse
La Revue Du Praticien|February 11, 2022
[Immunotherapy in oncology]Maxime Frelaut, Benjamin Besse
International Journal of Molecular Sciences|June 2, 2019
Hyperprogression under ImmunotherapyMaxime Frelaut, Christophe Le Tourneau, Edith Borcoman
Soins. Gerontologie|October 24, 2022
[The place of support care]Maxime Frelaut, Marion Aupomerol, Lena Degousée, et al.
Bulletin Du Cancer|April 10, 2021
[Why and how to assess older people with cancer?]Carole Helissey, Romain Geiss, Capucine Baldini, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 13, 2020
Pseudoprogression and Hyperprogression as New Forms of Response to ImmunotherapyMaxime Frelaut, Pauline du Rusquec, Alexandre de Moura, et al.
Cancer Treatment Reviews|April 26, 2022
The use of immunotherapy in older patients with advanced non-small cell lung cancerMarco Tagliamento, Maxime Frelaut, Capucine Baldini, et al.
Bulletin Du Cancer|April 26, 2021
[COVID-19 and patients with cancer: Experiment of a French comprehensive cancer center]Maxime Frelaut, Pauline Vaflard, Perrine Vuagnat, et al.
Cancers|December 11, 2019
Are Older Patients with Cervical Cancer Managed Differently to Younger Patients? An International SurveyMaxime Frelaut, Nienke De Glas, Ignacio Zapardiel, et al.
Age and Ageing|January 3, 2026
Reliability of the cumulative illness rating scale for geriatrics for assessing multimorbidity in older patients with cancer: results from the ELCAPA cohortMarc A Benderra, Philippe Caillet, Amélie Aregui, et al.
Pageof 3